Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022

View ORCID ProfileIsabel Bergeri, View ORCID ProfileMairead Whelan, View ORCID ProfileHarriet Ware, View ORCID ProfileLorenzo Subissi, View ORCID ProfileAnthony Nardone, View ORCID ProfileHannah C Lewis, View ORCID ProfileZihan Li, View ORCID ProfileXiaomeng Ma, View ORCID ProfileMarta Valenciano, Brianna Cheng, View ORCID ProfileLubna Al Ariqi, View ORCID ProfileArash Rashidian, View ORCID ProfileJoseph Okeibunor, View ORCID ProfileTasnim Azim, View ORCID ProfilePushpa Wijesinghe, View ORCID ProfileLinh-Vi Le, View ORCID ProfileAisling Vaughan, View ORCID ProfileRichard Pebody, View ORCID ProfileAndrea Vicari, Tingting Yan, View ORCID ProfileMercedes Yanes-Lane, View ORCID ProfileChristian Cao, David A. Clifton, View ORCID ProfileMatthew P Cheng, View ORCID ProfileJesse Papenburg, View ORCID ProfileDavid Buckeridge, View ORCID ProfileNiklas Bobrovitz, View ORCID ProfileRahul K Arora, View ORCID ProfileMaria D Van Kerkhove, the Unity Studies Collaborator Group
doi: https://doi.org/10.1101/2021.12.14.21267791
Isabel Bergeri
1World Health Organization, Geneva, Switzerland
PharmD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Isabel Bergeri
  • For correspondence: bergerii@who.int
Mairead Whelan
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mairead Whelan
Harriet Ware
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harriet Ware
Lorenzo Subissi
1World Health Organization, Geneva, Switzerland
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lorenzo Subissi
Anthony Nardone
1World Health Organization, Geneva, Switzerland
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anthony Nardone
Hannah C Lewis
1World Health Organization, Geneva, Switzerland
3World Health Organization, Regional Office for Africa, Brazzaville, Congo
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hannah C Lewis
Zihan Li
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
4Faculty of Engineering, University of Waterloo, Canada
BEng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zihan Li
Xiaomeng Ma
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
5Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaomeng Ma
Marta Valenciano
1World Health Organization, Geneva, Switzerland
6Epiconcept, Paris, France
DVM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marta Valenciano
Brianna Cheng
1World Health Organization, Geneva, Switzerland
7School of Population and Global Health, McGill University, Montreal, Quebec, Canada
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lubna Al Ariqi
8World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Egypt
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lubna Al Ariqi
Arash Rashidian
9World Health Organization, Regional Office for South-East Asia, New Delhi, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Arash Rashidian
Joseph Okeibunor
3World Health Organization, Regional Office for Africa, Brazzaville, Congo
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joseph Okeibunor
Tasnim Azim
9World Health Organization, Regional Office for South-East Asia, New Delhi, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tasnim Azim
Pushpa Wijesinghe
9World Health Organization, Regional Office for South-East Asia, New Delhi, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pushpa Wijesinghe
Linh-Vi Le
10World Health Organization, Regional Office for the Western Pacific, Manila, Philippines
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Linh-Vi Le
Aisling Vaughan
11World Health Organization Regional Office for Europe, Copenhagen, Denmark
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aisling Vaughan
Richard Pebody
11World Health Organization Regional Office for Europe, Copenhagen, Denmark
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Pebody
Andrea Vicari
12World Health Organization, Regional Office for the Americas (Pan American Health Organization), Washington DC, United States of America
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andrea Vicari
Tingting Yan
13Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
BHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mercedes Yanes-Lane
14COVID-19 Immunity Task Force Secretariat, McGill University, Montreal, Canada
MD, MScPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mercedes Yanes-Lane
Christian Cao
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Cao
David A. Clifton
15Institute of Biomedical Engineering, University of Oxford, UK
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew P Cheng
16Division of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matthew P Cheng
Jesse Papenburg
16Division of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada
MD, MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jesse Papenburg
David Buckeridge
16Division of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada
17Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Buckeridge
Niklas Bobrovitz
13Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
18Department of Critical Care Medicine, University of Calgary, Canada
DPhil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Niklas Bobrovitz
Rahul K Arora
2Centre for Health Informatics, Cumming School of Medicine, University of Calgary, Canada
15Institute of Biomedical Engineering, University of Oxford, UK
BHSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rahul K Arora
Maria D Van Kerkhove
1World Health Organization, Geneva, Switzerland
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Maria D Van Kerkhove
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Our understanding of the global scale of SARS-CoV-2 infection remains incomplete: routine surveillance data underestimates infection and cannot infer on population immunity, there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in WHO’s Unity protocol for general population seroepidemiological studies, two years into the pandemic, to estimate the extent of population infection and remaining susceptibility.

Methods and Findings We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between 2020-01-01 and 2022-05-20. The review protocol is registered with PROSPERO, (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies - those aligned with the WHO Unity protocol - were extracted and critically appraised in duplicate, with Risk of Bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate under-ascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. The main limitations of our methodology include that some estimates were driven by certain countries or populations being over-represented. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% LMIC) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/sub-national scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1-62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6-28.8] to 86.7% [84.6-88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3-11.0%] to 95.9% [92.6-97.8%] in Europe high-income countries in December 2021). After the emergence of Omicron, infection-induced seroprevalence rose to 47.9% [41.0-54.9%] in EUR HIC and 33.7% [31.6-36.0%] in AMR HIC in March 2022. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0-9 years and adults 60+ were at lower risk of seropositivity than adults 20-29 (p<0.0001 and p=0.005, respectively). In a multivariable model using pre-vaccination data, stringent public health and social measures were associated with lower seroprevalence (p=0.02).

Conclusions In this study, we observed that global seroprevalence has risen considerably over time and with regional variation, however around 40 % of the global population remains susceptible to SARS-CoV-2 infection. Our estimates of infections based on seroprevalence far exceed reported COVID-19 cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.

Competing Interest Statement

The authors of this manuscript have the following competing interests: RKA, MW, HW, ZL, XM, CC, MYL, DB, JP, MPC, ML, MS, GRD, NI, CZ, SP, HPR, TY, KCN, DK, SAA, ND, CD, NAD, EL, RKI, ASB, ELB, AS, JC and NB report grants from Canada's COVID-19 Immunity Task Force through the Public Health Agency of Canada, and the Canadian Medical Association Joule Innovation Fund. RKA, MW, HW, ZL, CC, MYL, NB also report grants from the World Health Organisation and the Robert Koch Institute. RKA reports personal fees from the Public Health Agency of Canada and the Bill and Melinda Gates Foundation Strategic Investment Fund, as well as equity in Alethea Medical (Outside the submitted work). MPC reports grants from McGill Interdisciplinary Initiative in Infection and Immunity and Canadian Institute of Health Research, and personal fees from GEn1E Lifesciences (Outside the submitted work), nplex biosciences (Outside the submitted work), Kanvas biosciences (Outside the submitted work). JP reports grants from MedImmune (Outside the submitted work) and Sanofi-Pasteur (Outside the submitted work), grants and personal fees from Merck (Outside the submitted work) and AbbVie (Outside the submitted work), and personal fees from AstraZeneca (Outside the submitted work). DB reports grants from the World Health Organization, Canadian Institutes of Health Research, Natural Sciences and Engineering Council of Canada (Outside the submitted work), Institute national d excellence en sante et service sociaux (Outside the submitted work), and personal fees from McGill University Health Centre (Outside the submitted work) and Public Health Agency of Canada (Outside the submitted work). CC reports funding from Sanofi Pasteur (Outside of the submitted work). TY reports working for Health Canada as a part-time Senior Policy Analyst with the COVID-19 Testing and Screening Expert Panel, from Nov 2020-Jun 2021 (Outside of the submitted work). TH reports funding recieved from the United States Centers for Disease Control and Prevention for Columbia University (Outside of the submitted work).

Funding Statement

This work was supported by WHO (WHO COVID-19 Solidarity Response Fund, to IB; German Federal Ministry of Health COVID-19 Research and Development Fund, to IB; World Health Organisation funding, to RKA), the Public Health Agency of Canada (Canada's COVID-19 Immunity Task Force through the Public Health Agency of Canada, to RKA), the Canadian Medical Association (Joule Innovation Fund, to RKA), and the Robert Koch Institute (funding to RKA). IB, LS, AnV, LA, AR, JO, TA, PW, LL, AiV, RP, MVK are employed and receive salaries from WHO (one of the funders of this study), and AN, MV, BC and HCL are WHO consultants. Authors who are members of the SeroTracker Group (led by RKA, including MW, HW, ZL, XM, TY, CC, MYL, JP, MPC, DB, ML, MS, GRD, NI, CZ, SP, HPR, TY, KCN, DK, SAA, ND, CD, NAD, EL, RKI, ASB, ELB, AS, JC) were supported through the aforementioned grants from WHO, Canada's COVID-19 Immunity Task Force through the Public Health Agency of Canada, the Robert Koch Institute, and the Canadian Medical Association Joule Innovation Fund. WHO had a role in the study design, data collection, data analysis, data interpretation, and the writing of the report. No other funders had any such role.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵** Full group author list is listed in the acknowledgements section

  • Extended search, initially was from Jan 2020 to Oct 2021 in v1, then covering the full first two years of the pandemic (Jan 2020-Dec 2021) in v2, and now covering Jan 2020-May 2022 search dates in v3.

Data Availability

Standardized results uploaded to Zenodo by UNITY study collaborators supporting the findings of this study are available at this community and DOIs for each included Zenodo study are cited in the Supplementary File (S5) https://zenodo.org/communities/unity-sero-2021?page=1&size=20. Detailed information on each study is available in Supplement S4. Other relevant data are available in a data repository (doi:10.5281/zenodo.5773152) and/or available from the Zenodo community upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 26, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022
Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, Anthony Nardone, Hannah C Lewis, Zihan Li, Xiaomeng Ma, Marta Valenciano, Brianna Cheng, Lubna Al Ariqi, Arash Rashidian, Joseph Okeibunor, Tasnim Azim, Pushpa Wijesinghe, Linh-Vi Le, Aisling Vaughan, Richard Pebody, Andrea Vicari, Tingting Yan, Mercedes Yanes-Lane, Christian Cao, David A. Clifton, Matthew P Cheng, Jesse Papenburg, David Buckeridge, Niklas Bobrovitz, Rahul K Arora, Maria D Van Kerkhove, the Unity Studies Collaborator Group
medRxiv 2021.12.14.21267791; doi: https://doi.org/10.1101/2021.12.14.21267791
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022
Isabel Bergeri, Mairead Whelan, Harriet Ware, Lorenzo Subissi, Anthony Nardone, Hannah C Lewis, Zihan Li, Xiaomeng Ma, Marta Valenciano, Brianna Cheng, Lubna Al Ariqi, Arash Rashidian, Joseph Okeibunor, Tasnim Azim, Pushpa Wijesinghe, Linh-Vi Le, Aisling Vaughan, Richard Pebody, Andrea Vicari, Tingting Yan, Mercedes Yanes-Lane, Christian Cao, David A. Clifton, Matthew P Cheng, Jesse Papenburg, David Buckeridge, Niklas Bobrovitz, Rahul K Arora, Maria D Van Kerkhove, the Unity Studies Collaborator Group
medRxiv 2021.12.14.21267791; doi: https://doi.org/10.1101/2021.12.14.21267791

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (280)
  • Allergy and Immunology (579)
  • Anesthesia (139)
  • Cardiovascular Medicine (1946)
  • Dentistry and Oral Medicine (252)
  • Dermatology (184)
  • Emergency Medicine (333)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (699)
  • Epidemiology (11102)
  • Forensic Medicine (8)
  • Gastroenterology (624)
  • Genetic and Genomic Medicine (3168)
  • Geriatric Medicine (308)
  • Health Economics (561)
  • Health Informatics (2042)
  • Health Policy (863)
  • Health Systems and Quality Improvement (782)
  • Hematology (310)
  • HIV/AIDS (682)
  • Infectious Diseases (except HIV/AIDS) (12720)
  • Intensive Care and Critical Care Medicine (707)
  • Medical Education (317)
  • Medical Ethics (92)
  • Nephrology (334)
  • Neurology (2986)
  • Nursing (164)
  • Nutrition (463)
  • Obstetrics and Gynecology (589)
  • Occupational and Environmental Health (614)
  • Oncology (1552)
  • Ophthalmology (477)
  • Orthopedics (185)
  • Otolaryngology (266)
  • Pain Medicine (202)
  • Palliative Medicine (57)
  • Pathology (403)
  • Pediatrics (912)
  • Pharmacology and Therapeutics (381)
  • Primary Care Research (355)
  • Psychiatry and Clinical Psychology (2784)
  • Public and Global Health (5591)
  • Radiology and Imaging (1093)
  • Rehabilitation Medicine and Physical Therapy (634)
  • Respiratory Medicine (759)
  • Rheumatology (338)
  • Sexual and Reproductive Health (311)
  • Sports Medicine (289)
  • Surgery (343)
  • Toxicology (48)
  • Transplantation (159)
  • Urology (132)